奥利万星对2011年至2015年从加拿大医院实验室分离出的革兰氏阳性病原体的体外活性。
In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015.
作者信息
Karlowsky James A, Walkty Andrew J, Baxter Melanie R, Arhin Francis F, Moeck Gregory, Adam Heather J, Zhanel George G
机构信息
Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada.
The Medicines Company, Ville Saint Laurent, Quebec, Canada.
出版信息
Diagn Microbiol Infect Dis. 2017 Apr;87(4):349-356. doi: 10.1016/j.diagmicrobio.2017.01.006. Epub 2017 Jan 20.
Gram-positive bacterial pathogens isolated from patient specimens submitted to 15 Canadian hospital laboratories from 2011 to 2015 were tested in the coordinating laboratory for susceptibility to oritavancin and comparative antimicrobial agents using the Clinical and Laboratory Standards Institute M07-A10 (2015) broth microdilution method. Oritavancin's in vitro activity was equivalent to, or more potent than, vancomycin, daptomycin, linezolid, and tigecycline against methicillin-susceptible Staphylococcus aureus (n=2680; oritavancin MIC, 0.12μg/mL; 99.9% oritavancin-susceptible), methicillin-resistant S. aureus (n=728; oritavancin MIC, 0.12μg/mL; 99.7% oritavancin-susceptible), Streptococcus pyogenes (n=218; oritavancin MIC, 0.25μg/mL; 100% oritavancin-susceptible), Streptococcus agalactiae (n=269; oritavancin MIC, 0.12μg/mL; 100% oritavancin-susceptible), and vancomycin-susceptible Enterococcus faecalis (n=508; oritavancin MIC, 0.06μg/mL; 100% oritavancin-susceptible). Oritavancin, dalbavancin, and telavancin demonstrated equivalent in vitro activities (MIC, μg/mL) against 602 isolates of MSSA (0.06, 0.06, 0.06, respectively) and 144 isolates of MRSA (0.12, 0.06, 0.06, respectively) collected in 2015.
从2011年至2015年提交给15家加拿大医院实验室的患者标本中分离出的革兰氏阳性细菌病原体，在协调实验室中使用临床和实验室标准协会M07 - A10（2015年）肉汤微量稀释法，检测其对奥利万星及比较性抗菌药物的敏感性。奥利万星对甲氧西林敏感金黄色葡萄球菌（n = 2680；奥利万星MIC，0.12μg/mL；99.9%对奥利万星敏感）、甲氧西林耐药金黄色葡萄球菌（n = 728；奥利万星MIC，0.12μg/mL；99.7%对奥利万星敏感）、化脓性链球菌（n = 218；奥利万星MIC，0.25μg/mL；100%对奥利万星敏感）、无乳链球菌（n = 269；奥利万星MIC，0.12μg/mL；100%对奥利万星敏感）以及万古霉素敏感粪肠球菌（n = 508；奥利万星MIC，0.06μg/mL；100%对奥利万星敏感）的体外活性等同于或强于万古霉素、达托霉素、利奈唑胺和替加环素。2015年收集的602株甲氧西林敏感金黄色葡萄球菌（分别为0.06、0.06、0.06μg/mL）和144株甲氧西林耐药金黄色葡萄球菌（分别为0.12、0.06、0.06μg/mL）中，奥利万星、达巴万星和替拉万星显示出相当的体外活性（MIC，μg/mL）。
Zotero 插件